Noveris Health Sciences is trading 14.81% down at $0.12 amid broad biotech weakness and a risk-off market session.
- Major indexes are also lower as investors respond to geopolitical tensions, higher oil prices, and softer labor and manufacturing data.
- No new company-specific announcement was identified for September 1, 2026.
- The latest financing proposal was an earlier C$500,000 convertible-debenture offering.